Select your country

North & South America

North & South America

Argentina

Local distributor

Argentina

JUSTESA IMAGEN ARGENTINA, S.A.

Viamonte 1328, 9º piso
1053 Buenos Aires
(Capital Federal)

ph. +5411 4373-0629
Canada
EN | FR
Colombia

Local distributor

Colombia

Sistemas Medicos, LTDA.

Apartado Aereo 24456
Calle 58 No. 35A61
Bogota
(Colombia)

ph. +571-221-9837
Fax +571-222-5310
Perù

Local distributor

Perù

REIMED, SCRL

Pasaje Villaran 192-194 U-12
Urb. Los Sauces Surquillo
Lima 15076
(Peru)

ph. 511-448-1087
Fax 511-448-3447
Uruguay

Local distributor

Uruguay

Lifenir S.A.

Justicia 2069
C 11800 Montevideo
(Uruguay)

ph. +5982-400-3020
Fax +5982-4007320
Venezuela

Local distributor

Venezuela

SUFOMECA

Torre Polar Oeste
Plaza Venezuela
Floor 7, Room 7C
Caracas
PO Box 1050
(Venezuela)

ph. +582-12-793-3222
Fax +582-12-781-1923

Europe

Europa

Bosnia-Herzegowina

Local distributor

Bosnia-Herzegowina

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719
Bulgaria

Local distributor

Bulgaria

EWOPHARMA AG

73 Persenk Street
App. 27 - Floor 8
1164 Sofia
(Bulgaria)

ph. +359 29624478
Fax +359 28683968
Croatia

Local distributor

Croatia

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719
Greece

Local distributor

Greece

LERIVA IMAGING S.A.

33 Pigis Avenue &
6 Anapiron Polemou Street
151 27 Melissia
Athens (Greece)

ph. +30 210-6199886
Fax +30 210 61 78 733
Malta

Local distributor

Malta

Suratek Ltd

Concordia Place
Triq Il-Halel
Bugibba SPB2529
Malta

ph. +356 2713 1624
Romania

Local distributor

Romania

EWOPHARMA A.G. ROMANIA

B-dul Primaverii 19 -21
Sc. B - Et.1 - Sect. 1
011972 - Bucharest
(Romania)

ph. +40 212601344
Fax +40 212029327
Serbia

Local distributor

Serbia

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719
Slovenia

Local distributor

Slovenia

MARK Srl

Via S. Michele 334
34170 Gorizia - Italy

ph. +39 0481 21711
Fax +39 0481 20719
Hungary

Local distributor

Ungheria

EWOPHARMA REPRESENTATION OFFICE

Budakeszi ut 73/F
H-1021 Budapest
(Hungary)

ph. +36 12004650
Fax +36 13980316

Eastern Europe, Middle East & Africa

Eastern Europe, Middle East & Africa

Ethiopia

Local distributor

Ethiopia

Caroga Pharma PVT. Ltd

P.O.Box 12627
Addis Abeba
(Ethiopia)

ph. +251 11 4654944 / 11 4161090
Fax +251 11 4654595
Ghana

Local distributor

Ghana

Cyndex Pharmacy

P.O.Box DS 1165 Dansoman
Accra
(Ghana)

ph. +233 21553370
Fax +233-244366622 / 21850072
Israel

Local distributor

Israel

DEXCEL

Or-Akiva 30600
30600000 Israel
(Israel)

ph. +972-4-6364015
Fax +972-4-6364004
Jordan

Local distributor

Jordan

THE ARAB DRUG STORE

Khaleel Al Salem street
Amman
(Jordan)

ph. +962 6 5502995
Fax +962 6 5502984
Kenya

Local distributor

Kenya

Nairobi X-Rays Supplies Ltd.

P.O. Box 41669
Nairobi
(Kenya)

ph. +254 20446265-6-7-8
Fax +254 20 4448515/17
Lebanon

Local distributor

Lebanon

Unione Pharmaceutic. d'Orient

Rue du Musée Imm. Stephan QtrBadaro
Beyrouth
(Lebanon)

ph. +961 1 396085-6
Fax +961 1 396047
Mauritius

Local distributor

Mauritius

The Mauritius Pharmacy

4, Louis Pasteur Str Forest Side
(Mauritius)

ph. +230 6762435
Fax +230 675 1387
Saudi Arabia

Local distributor

Saudi Arabia

SARABEEL COMMERCIAL EST.

Medical Division
P.O. BOX 14795
21434 Jeddah
(Saudi Arabia)

ph. +966 12657 2246
South Africa

Local distributor

South Africa

AXIM - Head Office Midrand

121 Gazelle Avenue
Corporate Park South
Midrand Johannesburg 2000
(South Africa)

ph. +27 113140140
Fax +27 113140141
Uganda

Local distributor

Uganda

Kampala X-Rays Suppliers

Plot 181 Bombo Rd (KuBbiri)
P.O. Box 9519
Kampala
(Uganda)

ph. +256 41 534313
Fax +256 41 349919
Ukraine

Local distributor

Ukraine

DELTA MEDlCAL

Delta Medical Promotions AG Representative Office
43 Chernovola Street
08132 Vyshneve, Kyiv region
Ukraine

ph. +38 445933355
United Arab Emirates

Local distributor

United Arab Emirates

MANARA HEALTHCARE

Concord Tower, 6th Floor
Dubai Media City
PO Box 213593, Dubai
United Arab Emirates

 

ph. +971 4 454 9712
Fax 971 4 454 2310

Asia Pacific

Asia Pacific

Australia

Local distributor

Australia

REGIONAL HEALTH CARE GROUP

3-11 Primrose Avenue Rosebery
NSW 2018 - Sydney
(Australia)

ph. +61 296624144
Fax +61 296626040
India

Local distributor

India

Imaging Products (India ) Ltd

Mumbai
(India)

ph. +91 9819725471
Fax +91 2228320208
Indonesia

Local distributor

Indonesia

PT DIPA PHARMALAB INTERSAINS

Jl. Panjang No. 10
Kebon Jeruk
Jakarta 11530
(Indonesia)

ph.  +62 215348644
Fax +62 2153676066
New Zealand

Local distributor

New Zealand

REGIONAL HEALTH LIMITED

19C Orbit Drive
Mairangi Bay
(New Zealand)

ph. +64 94140040
Fax +64 94140041
Pakistan

Local distributor

Pakistan

S. EJAZUDDIN & CO LTD

PO Box 5629 - Zia Plaza
Altaf Hussain Road
74000 Karachi
(Pakistan)

ph. +92 21212032
Fax +92 212629716
Philippines

Local distributor

Philippines

NEW MARKETLINK INTERNATIONAL CORP

Tao Corporate Centre 2291
Don Chino Roches Ave
Ext Makati City Metro
Manila (Philippines)

ph. (632) 836-5838
Singapore

Local distributor

Singapore

LF ASIA PHARMACEUTICAL DIVISION

Healthcare Distribution Centre
24 Penjuru Road (off Penjuru Close)
#03-04 CWT Commodity Hub
(Singapore 609128)

ph. +65 65097629
Taiwan

Local distributor

Taiwan

SUPER FORTUNE ENTERPRISE CO LTD

5 F-1 - 42 Sec.1 Ming
Sheng E. Road Jehovah Building
101 Taipei
(Taiwan)

ph. +886 225673456
Fax +886 225319231
Thailand

Local distributor

Thailand

Interpharmacare Co., Ltd.

90 Moo 13 Soi Mahacha
Bangpleeyai
Bangplee
Samutprakarn 10540
(Thailand)

ph. + 66 2 675 9140-2
Fax + 66 2 325 0265
Vietnam

Local distributor

Vietnam

HOANG GIA INVESCO, JSC

No 74-76 Hoa Bang Str
Cau Giay
Dist Ha Noi Hanoi
(Viet Nam)

ph. +43 7846952
 

Select your country

Asia

Australia

Local distributor

Australia

REGIONAL HEALTH CARE GROUP

3-11 Primrose Avenue Rosebery
NSW 2018 - Sydney
(Australia)

ph. +61 296624144
Fax +61 296626040
India

Local distributor

India

Imaging Products (India ) Ltd

Mumbai
(India)

ph. +91 9819725471
Fax +91 2228320208
Indonesia

Local distributor

Indonesia

PT DIPA PHARMALAB INTERSAINS

Jl. Panjang No. 10
Kebon Jeruk
Jakarta 11530
(Indonesia)

ph.  +62 215348644
Fax +62 2153676066
New Zealand

Local distributor

New Zealand

REGIONAL HEALTH LIMITED

19C Orbit Drive
Mairangi Bay
(New Zealand)

ph. +64 94140040
Fax +64 94140041
Pakistan

Local distributor

Pakistan

S. EJAZUDDIN & CO LTD

PO Box 5629 - Zia Plaza
Altaf Hussain Road
74000 Karachi
(Pakistan)

ph. +92 21212032
Fax +92 212629716
Philippines

Local distributor

Philippines

NEW MARKETLINK INTERNATIONAL CORP

Tao Corporate Centre 2291
Don Chino Roches Ave
Ext Makati City Metro
Manila (Philippines)

ph. (632) 836-5838
Singapore

Local distributor

Singapore

LF ASIA PHARMACEUTICAL DIVISION

Healthcare Distribution Centre
24 Penjuru Road (off Penjuru Close)
#03-04 CWT Commodity Hub
(Singapore 609128)

ph. +65 65097629
Taiwan

Local distributor

Taiwan

SUPER FORTUNE ENTERPRISE CO LTD

5 F-1 - 42 Sec.1 Ming
Sheng E. Road Jehovah Building
101 Taipei
(Taiwan)

ph. +886 225673456
Fax +886 225319231
Thailand

Local distributor

Thailand

Interpharmacare Co., Ltd.

90 Moo 13 Soi Mahacha
Bangpleeyai
Bangplee
Samutprakarn 10540
(Thailand)

ph. + 66 2 675 9140-2
Fax + 66 2 325 0265
Vietnam

Local distributor

Vietnam

HOANG GIA INVESCO, JSC

No 74-76 Hoa Bang Str
Cau Giay
Dist Ha Noi Hanoi
(Viet Nam)

ph. +43 7846952

North & South America

Argentina

Local distributor

Argentina

JUSTESA IMAGEN ARGENTINA, S.A.

Viamonte 1328, 9º piso
1053 Buenos Aires
(Capital Federal)

ph. +5411 4373-0629
Colombia

Local distributor

Colombia

Sistemas Medicos, LTDA.

Apartado Aereo 24456
Calle 58 No. 35A61
Bogota
(Colombia)

ph. +571-221-9837
Fax +571-222-5310
Perù

Local distributor

Perù

REIMED, SCRL

Pasaje Villaran 192-194 U-12
Urb. Los Sauces Surquillo
Lima 15076
(Peru)

ph. 511-448-1087
Fax 511-448-3447
Uruguay

Local distributor

Uruguay

Lifenir S.A.

Justicia 2069
C 11800 Montevideo
(Uruguay)

ph. +5982-400-3020
Fax +5982-4007320
Venezuela

Local distributor

Venezuela

SUFOMECA

Torre Polar Oeste
Plaza Venezuela
Floor 7, Room 7C
Caracas
PO Box 1050
(Venezuela)

ph. +582-12-793-3222
Fax +582-12-781-1923

Europe

Bosnia-Herzegowina

Local distributor

Bosnia-Herzegowina

Bulgaria

Local distributor

Bulgaria

EWOPHARMA AG

73 Persenk Street
App. 27 - Floor 8
1164 Sofia
(Bulgaria)

ph. +359 29624478
Fax +359 28683968
Croatia

Local distributor

Croatia

Greece

Local distributor

Greece

LERIVA IMAGING S.A.

33 Pigis Avenue &
6 Anapiron Polemou Street
151 27 Melissia
Athens (Greece)

ph. +30 210-6199886
Fax +30 210 61 78 733
Montenegro

Local distributor

Montenegro

Romania

Local distributor

Romania

EWOPHARMA A.G. ROMANIA

B-dul Primaverii 19 -21
Sc. B - Et.1 - Sect. 1
011972 - Bucharest
(Romania)

ph. +40 212601344
Fax +40 212029327
Serbia

Local distributor

Serbia

Slovenia

Local distributor

Slovenia

Ungheria

Local distributor

Ungheria

EWOPHARMA REPRESENTATION OFFICE

Budakeszi ut 73/F
H-1021 Budapest
(Hungary)

ph. +36 12004650
Fax +36 13980316

Eastern Europe, Middle East & Africa

Ethiopia

Local distributor

Ethiopia

Caroga Pharma PVT. Ltd

P.O.Box 12627
Addis Abeba
(Ethiopia)

ph. +251 11 4654944 / 11 4161090
Fax +251 11 4654595
Ghana

Local distributor

Ghana

Cyndex Pharmacy

P.O.Box DS 1165 Dansoman
Accra
(Ghana)

ph. +233 21553370
Fax +233-244366622 / 21850072
Israel

Local distributor

Israel

DEXCEL

Or-Akiva 30600
30600000 Israel
(Israel)

ph. +972-4-6364015
Fax +972-4-6364004
Jordan

Local distributor

Jordan

THE ARAB DRUG STORE

Khaleel Al Salem street
Amman
(Jordan)

ph. +962 6 5502995
Fax +962 6 5502984
Kenya

Local distributor

Kenya

Nairobi X-Rays Supplies Ltd.

P.O. Box 41669
Nairobi
(Kenya)

ph. +254 20446265-6-7-8
Fax +254 20 4448515/17
Lebanon

Local distributor

Lebanon

Unione Pharmaceutic. d'Orient

Rue du Musée Imm. Stephan QtrBadaro
Beyrouth
(Lebanon)

ph. +961 1 396085-6
Fax +961 1 396047
Mauritius

Local distributor

Mauritius

The Mauritius Pharmacy

4, Louis Pasteur Str Forest Side
(Mauritius)

ph. +230 6762435
Fax +230 675 1387
Saudi Arabia

Local distributor

Saudi Arabia

SARABEEL COMMERCIAL EST.

Medical Division
P.O. BOX 14795
21434 Jeddah
(Saudi Arabia)

ph. +966 12657 2246
South Africa

Local distributor

South Africa

AXIM - Head Office Midrand

121 Gazelle Avenue
Corporate Park South
Midrand Johannesburg 2000
(South Africa)

ph. +27 113140140
Fax +27 113140141
Uganda

Local distributor

Uganda

Kampala X-Rays Suppliers

Plot 181 Bombo Rd (KuBbiri)
P.O. Box 9519
Kampala
(Uganda)

ph. +256 41 534313
Fax +256 41 349919
Ukraine

Local distributor

Ukraine

DELTA MEDlCAL

Delta Medical Promotions AG Representative Office
43 Chernovola Street
08132 Vyshneve, Kyiv region
Ukraine

ph. +38 445933355

RESP product logo

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL is the first contrast agent indicated for both MRI of the CNS (>2 years) and MRA (adults) in the United States1

1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc. July 2013.

Thumbnails

RESP product logo

SDS

For more information about the safety of the MultiHance product line Download the Safety Data Sheet (PDF)

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL

accordion

MultiHance (gadobenate dimeglumine) injection, 529 mg/mL is a stable, linear, ionic gadolinium-based contrast agent (GBCA) known to have high thermodynamic and conditional stability.1,2 Based on its transient interactions with serum proteins, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL has greater relaxivity than the other GBCA approved for CNS imaging.1,3,4,5

In multiple clinical studies with intra-individual comparisons, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly improved visualization and contrast enhancement of central nervous system (CNS) lesions when compared with Gadavist®, 6 Dotarem®, 7 OmniscanTM 8 and Magnevist®.9

MultiHance (gadobenate dimeglumine) injection, 529 mg/mL was preferred among readers for all 5 qualitative endpoints:6-9

  • Global diagnostic preference
  • Lesion border delineation
  • Definition of disease extent
  • Visualization of lesion internal morphology
  • Lesion contrast enhancement

MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated excellent diagnostic performance in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.1,10-13

All trademarks and registered trademarks are the property of their respective owners.

1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc. July 2013. 2. Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009;30(6):1249–1258. 3. Shen Y, Goerner FL, Snyder C, et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol. 2015;50(5):330–338. 4.Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228. 5. Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR Am J Neuroradiol. 2008;29(4):668–673. 6. Seidl Z, Vymazal J, Mechl M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012;33(6):1050–1058. 7. Vaneckova M, Herman M, Smith MP, et al. The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study). AJNR Am J Neuroradiol. 2015;36(9):1589–1598. 8. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol. 2008;29(9):1684–1691. 9. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240(2):389–400. 10. Schneider G, Pasowicz M, Vymazal J, et al. Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: multicenter intraindividual crossover comparison. AJR Am J Roentgenol. 2010;195(2):476–485. 11. Gerretsen S, le Maire T, Miller S, et al. Multicenter double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of the peripheral arteries. Radiology. 2010;255:988-1000. 12. Wang J, Yan F, Liu J, et al. Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE study). J Magn Reson Imaging. 2013;38:926-937. 2013. 13. Wang CC, Liang HL, Hsiao CC, et al. Single-dose time-resolved contrast enhanced hybrid MR angiography in diagnosis of peripheral artery disease: compared with digital subtraction angiography. J Magn Reson Imaging. 2010;32:935-942.

MultiHance products are available in 5, 10, 15, and 20 mL single-dose vials, 50 and 100 mL Multipack (Pharmacy Bulk Packages*).

SINGLE-DOSE VIALS NDC Number
5 mL Vials 0270-5164-12
10 mL Vials 0270-5164-13
15 mL Vials 0270-5164-14
20 mL Vials 0270-5164-15

 

PHARMACY BULK PACKAGES NDC Number
50 mL Vials 0270-5264-16
100 mL Vials 0270-5264-17

*Not for direct infusion.

Find Out More and Download GHX Ordering Information

Questions?

  • Call Bracco Customer Service at 1-877-BRACCO-9 (1-877-272-2269), Option 2.

For more information on prescribing the MultiHance single dose vial

For more information on prescribing the MultiHance MultipackTM products

For more information about the safety of the MultiHance product line

Reimbursement coding information for the MultiHance product line. Please see important disclaimer information below.

Injectable Contrast Agents

MRI Products 2017 HCPCS Codes Short description Product SKU NDC: Unit Size: HCPCS Dosage: HCPCS Billing Units:
MultiHance® (gadobenate dimeglumine) Injection, 529 mg/mL A9577 Inj. MultiHance 5164-12 0270-5164-12 5x5 mL vials/box 1 mL 5
MultiHance® (gadobenate dimeglumine) Injection, 529 mg/mL A9577 Inj. MultiHance 5164-13 0270-5164-13 5x10 mL vials/box 1 mL 10
MultiHance® (gadobenate dimeglumine) Injection, 529 mg/mL A9577 Inj. MultiHance 5164-14 0270-5164-14 5x15 mL vials/box 1 mL 15
MultiHance® (gadobenate dimeglumine) Injection, 529 mg/mL A9577 Inj. MultiHance 5164-15 0270-5164-15 5x20 mL vials/box 1 mL 20
MultiHance® MultipackTM (gadobenate dimeglumine) Injection, 529 mg/mL A9578 Inj. MultiHance Multipack 5264-16 0270-5264-16 5x50 mL bottles/box 1 mL 50
MultiHance® MultipackTM (gadobenate dimeglumine) Injection, 529 mg/mL A9578 Inj. MultiHance Multipack 5264-17 0270-5264-17 5x50 mL bottles/box 1 mL 100

The information provided above is general reimbursement information for MultiHance products. It is not legal advice about how to code, complete, or submit any particular claim for payment. Although we supply this information based on our current knowledge, it is always the provider’s responsibility to determine and submit appropriate codes, charges, modifiers, and bills for the services that were rendered. This coding and reimbursement information is subject to change without notice. Payers or their local branches may have their own coding and reimbursement requirements and policies. Before filing any claims, providers should verify current requirements and policies with the payer.

Our reimbursement experts can assist you in finding answers to coding and reimbursement questions.

Contact the Bracco Reimbursement Hotline at:

Ask coding and billing questions regarding Bracco Diagnostics products and procedures related to those products.

  • Coding for products and procedures
  • Medicare payment

Bracco Diagnostics Inc. is pleased to provide customers with reimbursement support for products manufactured by the company and for medical procedures related to those products based on Medicare reimbursement policies. Because private payer coverage policies and benefit plans greatly differ, the information offered in this guide may not be applicable for billing and reporting to private payers. The treating provider is responsible for determining the medical necessity for each specific patient case. Claims submitted to payers should reflect the medical decisions made by the treating provider, current applicable state and federal regulations, and the provisions of the patient benefit plan. Bracco Diagnostics Inc. adheres to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) provisions and other applicable state and federal laws concerning the disclosure of protected health information (PHI). Our Reimbursement Services department does not enter into Business Associate Agreements (BAA) with customers. Therefore your institution should not disclose PHI to Bracco reimbursement representatives during the course of receiving reimbursement support.

Millions of doses,1 safety profile comparable to other CNS MRI contrast agents.2-5

Bracco Diagnostics Inc. maintains an ongoing commitment to patient safety. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL is safe for use in children (> 2 years) or those with renal insufficiency.2-5 The ACR categorizes MultiHance (gadobenate dimeglumine) injection, 529 mg/mL as a group 2 agent.3 In fact, there are no unconfounded cases of nephrogenic systemic fibrosis (NSF) with MultiHance (gadobenate dimeglumine) injection, 529 mg/mL in published, peer-reviewed literature.6

With more than 26 million doses administered worldwide,1 MultiHance (gadobenate dimeglumine) injection, 529 mg/mL has a comparable safety profile to other CNS MRI gadolinium-based contrast agents.2-5 In clinical trials, the majority of observed adverse events or reactions were transient, self-limiting, and mild in intensity. The most frequently reported adverse events were headache (1.2%) and nausea (1.3%).2

1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL global dosing from 2004 to 2015 and ProHance (Gadoteridol) Injection, 279.3 mg/mL global dosing from 1992 to 2015. (Data on file at Bracco Diagnostics Inc.) September 2015. 2. MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc. July 2013. 3.ACR Manual on Contrast Media. Version 10.2, 2016. 4. Soulez G, et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol. 2015; 205: 469-478. 5. Shellock FG, et al. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol. 2006; 41: 500-509. 6. Shellock FG, Crues JV III, editors. MRI: Bioeffects, Safety, and Patient Management. © 2014 by Biomedical Research Publishing Group, Los Angeles, CA.

Click here to link to the FDA NSF SAFETY UPDATE

Dr. Kevin DeMarco - Neuroradiologist - Walter Reed National Military Medical Center

Dr. Kenneth Maravilla - Professor of Radiology and Director of VMR Research Laboratory - University of Washington

Dr. Richard Semelka - Director of MR Services at the University of North Carolina - Professor of Radiology, Vice Chairman of Research

In multiple randomized clinical studies, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly improved visualization and contrast enhancement of CNS lesions when compared with Gadavist®, Dotarem®, Magnevist®, and OmniscanTM.1-4

Figure 1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist*

In the MERIT study, a multicenter, double-blind, randomized, intraindividual cross-over study of 123 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly higher lesion enhancement. In the image above, a 58-year-old woman with metastasis from melanoma underwent MR imaging for definite staging of metastatic disease. T1 GRE images reveal a metastasis in the right superior frontal gyrus. However, the lesion appears larger and shows more conspicuous enhancement with MultiHance (gadobenate dimeglumine) injection, 529 mg/mL than with Gadavist.1

Figure 2. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Dotarem*

In the BENEFIT study, a multicenter, double-blind, randomized, intraindividual cross-over study of 177 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly higher lesion enhancement. In the image above, a 53-year-old man with left parietal glioblastoma underwent MR imaging. An aggressive-appearing mass with inhomogeneous enhancement showed greater lesion enhancement on images obtained with MultiHance (gadobenate dimeglumine) injection, 529 mg/mL.2

Figure 3: MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Magnevist*

In the Maravilla, et al. study, a multicenter, double-blind, randomized, intraindividual cross-over study of 157 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly higher lesion enhancement. In the image above, a 51-year-old woman with metastatic lung cancer underwent MR imaging. Administration of MultiHance (gadobenate dimeglumine) injection, 529 mg/mL revealed meningeal carcinomatosis over the right frontal lobe and 2 additional metastatic nodules in the left frontal (upper arrow) and right occipital (lower arrow) areas not seen with Magnevist.3

Figure 4: MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Omniscan*

In the ENHANCE study, a multicenter, double-blind, randomized, intraindividual cross-over study of 138 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL resulted in significantly higher lesion enhancement. In the image above, a 55-year-old woman with recurrent glioblastoma underwent MR imaging. T1 GRE images show more conspicuous enhancement (arrow) in the right posterior temporal lobe with MultiHance (gadobenate dimeglumine) injection, 529 mg/mL.4

*These are representative images from reference studies, individual results may vary.
All trademarks and registered trademarks are the property of their respective owners.

"The greater definition and delineation of lesions combined with the increased potential for detection of small or otherwise poorly enhancing lesions with MultiHance might have considerable impact in terms of selecting the appropriate medical or surgical treatment to assure maximum benefit and improved patient outcomes." — Kuhn MJ, et al. J Neurosurg 20075

1. Seidl Z, Vymazal J, Mechl M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012;33(6):1050–1058. 2. Vaneckova M, Herman M, Smith MP, et al. The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study). AJNR Am J Neuroradiol. 2015;36(9):1589–1598. 3. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240(2):389–400. 4. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol. 2008;29(9):1684–1691. 5. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg. 2007 Apr;106(4):557-566.

Relaxivity is the physical principle that determines the extent to which gadolinium-based contrast agents (GBCAs) provide contrast enhancement on MR imaging. Agents with higher relaxivity deliver greater signal intensity.1 MultiHance (gadobenate dimeglumine) injection, 529 mg/mL differs from conventional agents in that its transient interactions with serum proteins result in increases in relaxivity at all serum ranges and commonly used field strengths.2-4

Higher relaxivity at all serum HSA levels

In the Giesel, et al. study, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL showed an exponentially increasing relaxation rate with increasing human serum albumin (HSA) concentration, while slight linear increases were seen for both Magnevist® and Gadavist®. At any given HSA concentration, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly greater relaxivity than Magnevist and Gadavist.2

Higher relaxivity at relevant field strengths

In the Rohrer, et al. study, a comparative study to determine the relaxivity of GBCAs, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated high relaxivity at all field strengths. In the image above, relaxivity is compared in plasma at 37°C at 1.5T. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL displays the highest relaxivity among commonly utilized GBCAs.3

All trademarks and registered trademarks are the property of their respective owners.

1. Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. Am J Neuroradiol. 2008;29(4):668–673. 2. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol. 2006;41(3):222–2288. 3. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715–724. 4. Shen Y, Goerner FL, Snyder C, et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7T. Invest Radiol. 2015; 50(5):330-338.

MRA

MultiHance (gadobenate dimeglumine) injection, 529 mg/mL is indicated for use in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.1 Readers consistently reported superior image quality in all segments when MultiHance (gadobenate dimeglumine) injection, 529 mg/mL was compared with Dotarem® at equal doses.2

All trademarks and registered trademarks are the property of their respective owners.

1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc. July 2012. 2. Wyttenbach R, Gianella S, Alerci M, Braghetti A, Cozzi L, Gallino A. Prospective blinded evaluation of Gd-DOTA¬–versus Gd-BOPTA enhanced peripheral MR angiography, as compared with digital subtraction angiography. Radiology. 2003;227(1):261-269.

MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; July 2013.

Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR Am J Neuroradiol. 2008.

ACR Manual on Contrast Media. Version 10.2, 2016.

Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol. 2006.

Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009.

Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006.

Maravilla KR, Smith MP, Vymazal J, et al. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual comparison of gadobutrol with gadoteridol (the TRUTH Study). AJNR Am J Neuroradiol. 2015.

Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol. 2008.

Schneider G, Pasowicz M, Vymazal J, et al. Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: multicenter intraindividual crossover comparison. AJR Am J Roentgenol. 2010.

Seidl Z, Vymazal J, Mechl M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012.

Shen Y, Goerner FL, Snyder C, et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol. 2015.

Vaneckova M, Herman M, Smith MP, et al. The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study). AJNR Am J Neuroradiol. 2015.

Gerretsen S, le Maire T, Miller S, et al. Multicenter double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of the peripheral arteries. Radiology. 2010.

Wang J, Yan F, Liu J, et al. Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE study). J Magn Reson Imaging. 2013.

Wang CC, Liang HL, Hsiao CC, et al. Single-dose time-resolved contrast enhanced hybrid MR angiography in diagnosis of peripheral artery disease: compared with digital subtraction angiography. J Magn Reson Imaging. 2010.

Soulez G, Bloomgarden DC, Rofsky NM, et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol. 2015.

Shellock FG, Parker JR, Pirovano G, et al. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol. 2006.

Shellock FG, Crues JV III, editors. MRI: Bioeffects, Safety, and Patient Management. © 2014 by Biomedical Research Publishing Group, Los Angeles, CA.

Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg. 2007 Apr;106(4):557-566.

Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715–724.

Wyttenbach R, Gianella S, Alerci M, Braghetti A, Cozzi L, Gallino A. Prospective blinded evaluation of Gd-DOTA¬–versus Gd-BOPTA enhanced peripheral MR angiography, as compared with digital subtraction angiography. Radiology. 2003.

RESP product logo

Find your local rep

Contacts

Customer Service 1-877-BRACCO-9
(1-877-272-2269), Option 2

Drug Safety

1-800-257-5181, Option 1

Professional Services

1-800-257-5181, Option 2

Indications and Usage

Indications and Usage:
MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL is indicated for intravenous use in MRI of the central nervous system in adults and children over 2 years of age to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues. It is also approved for MRA to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

IMPORTANT SAFETY INFORMATION:

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended MultiHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration. [see Warnings and Precautions (5.1)]

Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations ranging from mild to severe. The possibility of a reaction should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

Please see full Prescribing Information for MultiHance (gadobenate dimeglumine) injection, 529 mg/mL including boxed WARNING by clicking here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

MultiHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia S.p.A., Ferentino, Italy.

MultiHance is a registered trademark of Bracco International B.V.

MultiHance Multipack is a trademark of Bracco International B.V.

All trademarks and registered trademarks are the property of their respective owners.